Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Bacopa Monnieri | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands) | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Ongoing; benefits accumulate over months. No strict cycling required. | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | strong_human | moderate_human |
Active triterpenoid saponins (bacosides A and B) provide multifaceted neuroprotection: inhibition of acetylcholinesterase (AChE) and activation of choline acetyltransferase (ChAT) to enhance cholinergic neurotransmission; upregulation of tryptophan hydroxylase and serotonin transporter expression to modulate serotonergic tone; antioxidant neuroprotection via induction of superoxide dismutase and glutathione peroxidase; and reduction of beta-amyloid aggregation. Additionally enhances GABA signaling through GABA-A receptor subunit upregulation and glutamate decarboxylase activation.
300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands)
With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects.
Ongoing; benefits accumulate over months. No strict cycling required.
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →